Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia Journal Article


Authors: Topp, M. S.; Stelljes, M.; Zugmaier, G.; Barnette, P.; Heffner, L. T. Jr; Trippett, T.; Duell, J.; Bargou, R. C.; Holland, C.; Benjamin, J. E.; Klinger, M.; Litzow, M. R.
Article Title: Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
Keywords: treatment outcome; overall survival; fatigue; neutropenia; paresthesia; diarrhea; drug efficacy; drug safety; drug withdrawal; side effect; letter; edema; multiple cycle treatment; anemia; leukopenia; thrombocytopenia; continuous infusion; acute lymphoblastic leukemia; coughing; febrile neutropenia; fever; bone marrow biopsy; brain disease; muscle weakness; allogeneic hematopoietic stem cell transplantation; epilepsy; leukemia relapse; epistaxis; retreatment; tachycardia; leukemia remission; myopathy; randomized controlled trial (topic); disorientation; blinatumomab; human; priority journal; b precursor acute lymphoblastic leukemia
Journal Title: Leukemia
Volume: 32
Issue: 2
ISSN: 0887-6924
Publisher: Nature Publishing Group  
Date Published: 2018-02-01
Start Page: 562
End Page: 565
Language: English
DOI: 10.1038/leu.2017.306
PROVIDER: scopus
PMCID: PMC5808068
PUBMED: 28990581
DOI/URL:
Notes: Letter -- Export Date: 2 April 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Tanya M Trippett
    126 Trippett